問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Principal Investigator

蘇五洲

List

137Cases

2014-10-01 - 2023-03-16

Phase III

A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) versus Platinum Based Chemotherapy in Treatment Naïve Subjects with PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer (Keynote 042)

  • Condition/Disease

    Non-Small Cell Lung Cancer (NSCLC)

  • Test Drug

    MK-3475

Participate Sites
5Sites

Terminated5Sites

2013-03-01 - 2020-12-10

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2010-03-01 - 2012-12-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2019-01-01 - 2021-05-20

Phase II

Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non–Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib

  • Condition/Disease

    ALK-positive Advanced NSCLC

  • Test Drug

    Brigatinib

Participate Sites
5Sites

Recruiting4Sites

2015-09-09 - 2017-11-30

Phase III

TIGER-3: A Phase 3, Open-label, Multicenter, Randomized Study of Oral Rociletinib (CO-1686) Monotherapy Versus Single-agent Cytotoxic Chemotherapy in Patients with Mutant EGFR Non-small Cell Lung Cancer (NSCLC) after Failure of at Least 1 Previous EGFR-directed Tyrosine Kinase Inhibitor (TKI) and Platinumdoublet Chemotherapy

  • Condition/Disease

    Non-Small Cell Lung Cancer (NSCLC)

  • Test Drug

    CO-1686 Hydrobromide Film-Coated Tablet

Participate Sites
6Sites

Terminated5Sites

夏德椿
China Medical University Hospital-Taipei

未分科

陳育民
Taipei Veterans General Hospital

Division of Thoracic Medicine

2015-09-01 - 2018-03-31

Phase II

A phase 2, parallel group, to explore the study of MGCD265 in patients with locally advanced or metastatic non-small cell lung cancer with active gene mutations in mesenchymal-epithelial transforming factor

  • Condition/Disease

    NSCLC

  • Test Drug

    MGCD265

Participate Sites
6Sites

Terminated6Sites

2017-03-14 - 2020-11-01

Phase III

A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) Versus Crizotinib in Patients With ALK-positive Advanced Lung Cancer

  • Condition/Disease

    ALK-positive advanced lung cancer

  • Test Drug

    Brigatinib (AP26113)

Participate Sites
6Sites

Recruiting5Sites

夏德椿
China Medical University Hospital-Taipei

未分科

陳育民
Taipei Veterans General Hospital

Division of Thoracic Medicine

2009-07-01 - 2011-07-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2012-09-01 - 2016-12-31

Phase III

A Multi-center, Open-Label, Adaptive, Randomized Study of Palifosfamide-tris, a Novel DNA Crosslinker, in Combination with Carboplatin and Etoposide (PaCE) Chemotherapy versus Carboplatin and Etoposide (CE) Alone in Chemotherapy Naïve Patients with Extensive-Stage Small Cell Lung Cancer. The MATISSE Study

  • Condition/Disease

    Small cell lung cancer

  • Test Drug

    Palifosfamide-tris

Participate Sites
7Sites

Terminated7Sites

2020-06-01 - 2022-02-09

Phase III

A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C

  • Condition/Disease

    Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C

  • Test Drug

    AMG 510

Participate Sites
4Sites

Recruiting4Sites

1 6 7 8 9 10 14
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB